Tag: J&J
J&J presents early outcomes from OMNY-AF pilot study alongside new Varipulse...
Johnson & Johnson (J&J) has announced 12-month pilot-phase data from the OMNY-AF study evaluating its investigational Omnypulse platform for the treatment of symptomatic paroxysmal...
J&J to showcase PFA advancements via multiple clinical and real-world studies...
Johnson & Johnson (J&J) MedTech has announced that new clinical and real-world data from its integrated-by-design Varipulse platform in pulsed field ablation (PFA) procedures for...
J&J unveils real-world results from VARIPURE substudy at ESC 2025
Johnson & Johnson (J&J) MedTech has today announced acute safety and effectiveness results from the VARIPURE substudy of the SECURE study evaluating the company’s Varipulse...
J&J MedTech announces US launch of ICE catheter for use in...
Johnson & Johnson (J&J) MedTech has announced the US launch of the Soundstar Crystal ultrasound catheter for intracardiac echocardiography (ICE) imaging in cardiac ablation procedures.
The...
J&J MedTech presents new Omny-IRE and VARIPURE study data at HRS...
Johnson & Johnson (J&J) MedTech has announced positive initial three-month results from the Omny-IRE study evaluating the investigational Omnypulse platform in patients with paroxysmal...
J&J’s dual-energy ablation catheter deemed safe and effective in first-in-human SmartfIRE...
Johnson & Johnson (J&J) MedTech has today announced 12-month results from the SmartfIRE study, delivered as a late-breaking presentation at the ongoing European Heart...
J&J to resume Varipulse cases following ‘voluntary pause’ of US external...
Following a temporary, voluntary pause of US external evaluation and all US cases with its Varipulse catheter, Johnson & Johnson (J&J) is set to...
Cerenovus and Biosense Webster among brands newly incorporated into Johnson &...
Johnson & Johnson (J&J) recently shared that its medical technology businesses—including Cerenovus and Biosense Webster, as well as Abiomed, DePuy Synthes, and Ethicon—will now...